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Abstract
Background: Mycobacterium tuberculosis is a leading cause of death worldwide. In multi-drug
resistant tuberculosis (MDR-TB) infectiousness is frequently prolonged, jeopardizing efforts to
control TB. The conventional tuberculosis drug susceptibility tests are sensitive and specific, but
they are not rapid. The INNO-LiPA Rif. TB ® (LiPA) is a commercial line probe assay designed to
rapidly detect rifampicin resistance, a marker of MDR-TB. Although LiPA has shown promising
results, its overall accuracy has not been systematically evaluated.
Methods: We did a systematic review and meta-analysis to evaluate the accuracy of LiPA for the
detection of rifampicin-resistant tuberculosis among culture isolates and clinical specimens. We
searched Medline, Embase, Web of Science, BIOSIS, and Google Scholar, and contacted authors,
experts and the manufacturer. Fifteen studies met our inclusion criteria. Of these, 11 studies used
culture isolates, one used clinical specimens, and three used both. We used a summary receiver
operating characteristic (SROC) curve and Q* index to perform meta-analysis and summarize
diagnostic accuracy.
Results: Twelve of 14 studies that applied LiPA to isolates had sensitivity greater than 95%, and
12 of 14 had specificity of 100%. The four studies that applied LiPA directly to clinical specimens
had 100% specificity, and sensitivity that ranged between 80% and 100%. The SROC curve had an
area of 0.99 and Q* of 0.97.
Conclusion: LiPA is a highly sensitive and specific test for the detection of rifampicin resistance in
culture isolates. The test appears to have relatively lower sensitivity when used directly on clinical
specimens. More evidence is needed before LiPA can be used to detect MDR-TB among
populations at risk in clinical practice.
Published: 28 July 2005
BMC Infectious Diseases 2005, 5:62 doi:10.1186/1471-2334-5-62
Received: 14 April 2005
Accepted: 28 July 2005
This article is available from: http://www.biomedcentral.com/1471-2334/5/62
© 2005 Morgan et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2005, 5:62 http://www.biomedcentral.com/1471-2334/5/62
Page 2 of 9
(page number not for citation purposes)
Background
Tuberculosis (TB) continues to be a major public health
problem, particularly in developing countries. The WHO
estimates that one third of the world's population is
infected with Mycobacterium tuberculosis, the causative
agent of TB. There were an estimated 8.3 million new
active cases and 1.8 million deaths from TB in the year
2000, making it the second greatest killer among infec-
tious diseases worldwide [1].
The prevalence of multidrug-resistant TB (MDR-TB),
defined as resistance to at least rifampicin (RIF) and isoni-
azid (INH), is rising in a number of geographic regions.
According to a recent WHO report [1], the median preva-
lence of MDR-TB is 1% (range 0%–14.1%) among new
cases and 9.3% (range 0%–48%) among previously
treated cases. Rapid identification is essential for effective
treatment and control of MDR-TB. Conventional methods
of drug susceptibility testing (DST) include solid media-
based methods such as the proportion, absolute concen-
tration, and resistance ratio methods. These can take up to
12 weeks to produce definitive results, leading to pro-
longed infectiousness [2]. Liquid media-based tests, such
as the BACTEC®, MB/BacT®, ESP® and MGIT® systems, are
more rapid, but also more costly and require sophisticated
laboratories and trained personnel [2].
Rifampicin works by binding to the beta-subunit of the
RNA polymerase (coded for by the rpoB gene), inhibiting
protein transcription [3]. DNA sequencing studies have
shown that greater than 95% of the RIF-resistant strains
have mutations within an 81 base pair hot-spot region
(codons 507–533) of the rpoB gene [4]. Though more
than 50 mutations within this region have been character-
ized by automated DNA sequencing, the majority involve
point mutations at codons 516, 526, or 531 [5]. It is esti-
mated that more than 90% of RIF-resistant TB is also
resistant to INH, making RIF-resistance a good surrogate
marker for MDR-TB [4,6]. The above observations have
lead to the recent development of several genotypic meth-
ods for rapidly detecting RIF-resistance conferring muta-
tions, including DNA sequencing, line probe assay, single-
strand conformation polymorphism, DNA microarrays,
RNA/RNA mismatch, and molecular beacons [2].
The commercially available INNO-LiPA Rif. TB kit (Inno-
genetics, Zwijndrecht, Belgium) is a line probe assay
(LiPA) able to identify the M. tuberculosis complex and
simultaneously detect genetic mutations in the rpoB gene
region related to RIF-resistance [7]. The LiPA kit contains
10 oligonucleotide probes (one specific for the M. tubercu-
losis complex, five overlapping wild-type S probes, and
four R probes for detecting specific mutations of resistant
genotypes) immobilized on nitrocellulose paper strips
[7].
LiPA is performed by extracting DNA from cultures or
directly from clinical samples and amplifying the RIF-
resistance-determining region of the rpoB gene using PCR.
Biotinylated PCR products are then hybridized with the
immobilized probes, and results are determined by color-
imetric development. The M. tuberculosis isolate is consid-
ered RIF susceptible if all of the wild-type S probes give a
positive signal and all of the R probes react negatively. RIF
resistance is indicated by absence of one or more wild-
type S probes. When RIF resistance is due to one of the
four most frequently observed mutations, a positive reac-
tion is obtained with one of the four R probes [7].
A number of studies [3,5,7-19] have evaluated the diag-
nostic accuracy of LiPA for detecting RIF resistance in
diverse geographic settings. We conducted a systematic
review and meta-analysis to evaluate the overall accuracy
of line probe assay in the detection of RIF-resistant TB.
Methods
Search strategy
We searched the following databases for retrieving articles
and abstracts based on primary studies: Pubmed, Embase,
Biosis, Web of Science (all 1990–2004), and Google
Scholar (December 2004) using the keywords and search
terms "Tuberculosis", "Mycobacterium tuberculosis",
"Tuberculosis, Multidrug-Resistant", "Drug Resistance",
"Drug Resistance, Bacterial", "rifampicin", "Rifampin",
"mutation", "mutant", "rpob", "rpob gene", "line probe",
"line probe assay", "LiPA", and "INNO-LiPA". We also
contacted authors and experts, including the manufac-
turer of the commercial INNO-LiPA Rif.Tb kit, for lists of
references and unpublished data, and reviewed citations
of relevant primary studies and review articles.
Study selection
We identified results from all primary studies evaluating
the accuracy (sensitivity and specificity) of line probe
assay (specifically, the commercial INNO-LiPA Rif. TB kit)
for rapid detection of RIF-resistant TB in clinical speci-
mens or isolates. Titles and/or abstracts of all citations
were screened independently by two reviewers (MM and
SK), with 85% agreement on articles warranting full text
review. Differences between reviewers were reconciled by
consensus, and the full text of all relevant studies was
evaluated.
We included studies that met the following pre-deter-
mined criteria: (i) comparison of INNO-LiPA with a refer-
ence standard (including proportion method, radiometric
BACTEC 460 method, and minimum inhibitory concen-
tration method), (ii) evaluation of a minimum of ten RIF-
sensitive and ten RIF-resistant samples.BMC Infectious Diseases 2005, 5:62 http://www.biomedcentral.com/1471-2334/5/62
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Although our initial search had no language restrictions,
studies not available in either English or Spanish language
were excluded from the data extraction process.
Data extraction and assessment of study quality
All included articles were assessed by one reviewer (MM),
who extracted data using a piloted data extraction form. A
second reviewer (LF) independently extracted data from a
subset (five out of fifteen) of the included studies, with an
inter-rater agreement between the two reviewers of 80%
for sensitivity and specificity data. Discrepancies between
reviewers were reconciled by consensus. Extracted data
included the reference standard used, type of sample
(clinical specimen vs. isolate), outcome data (sensitivity
and specificity as determined by comparison with the ref-
erence standard), and proportion of RIF-resistant samples
that were determined to be MDR-TB.
We assessed study quality using the following criteria,
based on the QUADAS criteria [20] for assessment of
quality of diagnostic studies: (i) prospective enrolment of
consecutive patients, (ii) comparison with an appropriate
reference standard, (iii.) blind and independent compari-
son of the index test (LiPA) with a reference standard, and
(iv) verification (partial or complete) of LiPA results by
reference standards.
Data synthesis and meta-analysis
We used standard methods for diagnostic meta-analysis
[23,24], and performed data analysis using the Meta-Disc
(version 1.1.1) software [23].
We focused on sensitivity and specificity as measures of
diagnostic accuracy of LiPA. These were computed by cre-
ating a two by two table of LiPA RIF-susceptibility results
against reference standard RIF-susceptibility results for
each study and cross-tabulating. Sensitivity (true positive
rate [TPR]) in this case is defined as the proportion of
samples determined to be RIF-resistant by a reference
standard correctly identified as RIF-resistant by LiPA. Spe-
cificity (true negative rate or 1-false positive rate [FPR]) is
defined as the proportion of samples determined to be
RIF-sensitive by a reference standard correctly identified as
RIF-sensitive by LiPA. We created forest plots to display
estimates of accuracy and examine the heterogeneity
(between-study variability) of the summary measures of
sensitivity and specificity.
We summarized the joint distribution of TPR and FPR
with a summary receiver operating characteristic (SROC)
curve. SROC curves used in analyses of diagnostic accu-
racy are intended to represent the relationship between
TPR and FPR across studies when test performance is eval-
uated at varying diagnostic thresholds [24]. Each study is
a separate unit of analysis and contributes an estimate of
TPR and FPR. Overall diagnostic performance of a test can
be judged by the position and appearance of the SROC
curve, which is fitted by using a regression model pro-
posed by Moses et al [25]. The area under the curve (AUC)
represents an overall summary measure of the curve and
the test's overall ability to accurately distinguish cases
from non-cases. The Q* index, the highest point on the
SROC curve that intersects the anti-diagonal, represents a
summarization of test performance where sensitivity and
specificity are equal (so the probability of an incorrect test
result is the same for cases and non-cases). An AUC of one
represents perfect discriminatory ability, while a Q* index
of one represents perfect accuracy [24].
Results
Description of included studies
Figure 1 illustrates the study selection process. Fifteen arti-
cles [3,5,7-19], all reporting results of primary studies,
met eligibility criteria and are included in this review.
Table 1 describes the characteristics and outcomes of the
15 included studies. Three studies [10,11,19] are listed
twice in order to describe the outcome of a subgroup anal-
ysis of LiPA applied directly to clinical specimens. All
studies were published between 1995 and 2004 and used
the commercial INNO-LiPA Rif. TB kit according to the
manufacturer's instructions. Eleven studies [3,5,7,12-18]
tested LiPA exclusively on culture isolates, one study [8]
tested LiPA directly on clinical specimens, and three stud-
ies [10,11,19] tested LiPA on both isolates and clinical
specimens. Clinical specimens included sputum,
Study selection process and reasons for exclusion of studies Figure 1
Study selection process and reasons for exclusion of studies.BMC Infectious Diseases 2005, 5:62 http://www.biomedcentral.com/1471-2334/5/62
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bronchial aspirate, urine, tissue biopsy, cerebrospinal
fluid, feces, skin exudates, and gastric juice aspirate.
The 15 studies evaluated 1738 specimens (mean 91; range
20 to 411), 1164 (67%) of which were RIF-resistant.
Twelve of the 15 studies include a greater number of RIF-
resistant than RIF-sensitive strains (mean 87 and 36
respectively). Six studies [3,7-9,15,18] used proportion
method, six studies [5,10-12,14,17] used BACTEC 460,
two studies [13,19] used both proportion method and
BACTEC 460, and one study [16] used minimum inhibi-
tory concentration (MIC) method as the reference test.
Only two studies [13,19] explicitly reported blinding
researchers to the results of the reference standard and/or
LiPA. None of the studies prospectively enrolled consecu-
tive patients, and all had complete verification of LiPA
with a reference standard.
Accuracy of LiPA in isolates
Figure 2 illustrates a forest plot of estimates of sensitivity
and specificity based on results of the 15 included studies
and stratified by type of sample (isolate vs. clinical speci-
men). Figure 3 is a SROC curve of the same data. As seen
in figure 2, of the 14 studies that applied LiPA to isolates,
sensitivity ranged from 82% to 100%, and specificity
ranged from 92% to 100%. Twelve studies [5,7,9-15,17-
19] reported sensitivity >= 95%, and five of these studies
[10,12,13,17,19] reported sensitivity of 100%. With the
exception of two [12,19], all studies reported specificity of
100%.
The SROC curve, figure 3, shows an area of 0.99 and Q*
of 0.97, indicating a high level of overall accuracy.
Subgroup analysis of accuracy of LiPA in clinical specimens
As illustrated in figure 2, of the four studies that tested
LiPA directly on clinical specimens [8,10,11,19], sensitiv-
ity estimates, although more variable than specificity, are
consistently high (80% to 100%) with one study [11]
reporting a sensitivity of 100%. The specificity estimates
for all four studies are 100%.
Although still consistently high, sensitivity appears to be
lower overall in clinical specimens than isolates.
Additionally, one study [11] explicitly stated that 13 of the
60 samples tested were indeterminate due to failure at the
PCR stage, making it impossible to perform LiPA. These
are excluded from measures of sensitivity and specificity,
indicating that the overall accuracy of LiPA applied to clin-
ical specimens may be inflated in this study (and possibly
others if they experienced similar indeterminate results
that went unreported) when compared with performance
in an actual clinical setting.
Table 1: Description of studies included in meta-analysis.
Author (year) Country Reference 
Test
Blinded to 
reference 
test?
Sample Sample size 
(# resistant / 
# sensitive)
Sensitivity 
(95% CI)
Specificity 
(95% CI)
Ahmad (2002) Kuwait BACTEC 460 Not Specified Isolate 29/12 0.97 (.82–1.0) 1.0 (.74–1.0)
De Oliveira (1998) Brazil Proportion Not Specified Isolate 113/15 0.97 (.92–.99) 1.0 (.78–1.0)
Gamboa (1998) Spain BACTEC 460 Not Specified Isolate 46/13 1.0 (.92–1.0) 1.0 (.75–1.0)
Hirano (1999) Japan Proportion Not Specified Isolate 90/26 0.92 (.85–.97) 1.0 (.87–1.0)
Johansen (2003) Denmark BACTEC 460 Not Specified Isolate 35/24 0.97 (.85–1.0) 1.0 (.86–1.0)
Jureen (2004) Sweden BACTEC 460 Not Specified Isolate 27/26 1.0 (.87–1.0) 0.92 (.75–.99)
Lemus (2004) Belgium BACTEC 460, 
Proportion
Yes Isolate 10/10 1.0 (.69–1.0) 1.0 (.69–1.0)
Rossau (1997) Belgium Proportion Not Specified Isolate 203/61 0.98 (.95–.1.0) 1.0 (.94–1.0)
Sintchenko (1999) Australia BACTEC 460 Not Specified Isolate 22/11 0.96 (.77–1.0) 1.0 (.72–1.0)
Somoskovi (2003) USA Proportion Not Specified Isolate 64/37 0.95 (.87–.99) 1.0 (.91–1.0)
Srivastava (2004) India MIC Not Specified Isolate 45/10 0.82 (.68–.92) 1.0 (.69–1.0)
Tracevska (2002) Latvia BACTEC 460 Not Specified Isolate 34/19 1.0 (.90–1.0) 1.0 (.82–1.0)
Traore (2000) Belgium Proportion Not Specified Isolate 266/145 0.99 (.96–1.0) 1.0 (.98–1.0)
Watterson (1998) England BACTEC 460, 
Proportion
Not Specified Isolate 16/16 1.0 (.80–1.0) 0.94 (.70–1.0)
De Beenhouwer (1995) Belgium Proportion Not Specified Clinical Specimen 21/46 0.91 (.70–1.0) 1.0 (.92–1.0)
Gamboa (1998) Spain BACTEC 460 Not Specified Clinical Specimen 46/13 0.98 (.89–1.0) 1.0 (.75–1.0)
Johansen (2003) Denmark BACTEC 460 Not Specified Clinical Specimen 26/21 1.0 (.87–1.0) 1.0 (.84–1.0)
Watterson (1998) England BACTEC 460, 
proportion
Yes Clinical Specimen 10/24 0.80 (.44–.98) 1.0 (.86–1.0)BMC Infectious Diseases 2005, 5:62 http://www.biomedcentral.com/1471-2334/5/62
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Forrest plots of sensitivity and specificity Figure 2
Forrest plots of sensitivity and specificity. The point estimates of sensitivity and specificity from each study are shown as 
solid circles (culture isolates) and open rectangles (clinical specimens). Error bars are 95% confidence intervals (CI).BMC Infectious Diseases 2005, 5:62 http://www.biomedcentral.com/1471-2334/5/62
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Rifampicin-resistance as a marker of MDR-TB
Four studies [5,8,12,18] determined the number of RIF-
resistant samples that were also INH-resistant, thereby
meeting the criteria for MDR-TB. On average, 91% of RIF-
resistant samples were also INH-resistant.
Discussion
Principle findings
This meta-analysis suggests that the LiPA assay is highly
sensitive and specific for detecting rifampicin-resistant TB
both in culture isolates and, to a slightly lesser degree,
clinical specimens. The majority of studies had sensitivity
of 95% or greater, and nearly all were 100% specific.
Despite variations in patient populations, all 15 studies
yielded consistently high estimates of sensitivity and spe-
cificity, so heterogeneity was not a concern in this meta-
analysis [26].
Clinical implications
The currently employed DST methods typically delay the
diagnosis of MDR-TB by at least one to two months. A
more rapid method is needed to allow timely diagnosis
and initiation of effective treatment. This meta-analysis
demonstrates that LiPA yielded high overall sensitivity
and specificity with a maximum joint sensitivity and spe-
cificity of 97% (based on the Q* index). The test may thus
Summary Receiver Operator Curve (SROC) plot for line probe assay Figure 3
Summary Receiver Operator Curve (SROC) plot for line probe assay. Each solid circle (culture isolate) and open 
rectangle (clinical specimen) represents each study in the meta-analysis. The curve is the regression line that summarizes the 
overall diagnostic accuracy. SROC: summary receiver operating characteristic; AUC: area under the curve; SE(AUC): standard 
error of AUC; Q*: an index defined by the point on the SROC curve where the sensitivity and specificity are equal, which is 
the point closest to the top-left corner of the ROC space; SE(Q*): standard error of Q* index.BMC Infectious Diseases 2005, 5:62 http://www.biomedcentral.com/1471-2334/5/62
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have a potential role in ruling in and ruling out the diag-
nosis of RIF-resistance. For example, assuming that 5% of
TB patients in a clinical setting have RIF-resistant TB, a
positive LiPA result (inferring RIF-resistance) would yield
a positive predictive value of 83%, while a negative LiPA
result would yield a negative predictive value of 99%.
These test results would lead to a clinically meaningful
increase in the probability of RIF-resistance from 5% to
83% if a test is positive, while a negative test would
virtually rule out RIF-resistance. Because the test has a
high sensitivity, a negative result would effectively rule
out the probability of drug resistance. Similarly, because
the test has a high specificity, a positive result would rule
in drug resistance. However, the diagnostic accuracy of
LiPA needs to be interpreted cautiously in low prevalence
areas. For example, if the baseline prevalence of
rifampicin resistance is 1%, a positive test would translate
into a positive predictive value of only 66%, i.e. one false
positive test for every two true positives. As with any diag-
nostic test, if used judiciously (ie in patients suspected of
having MDR-TB, thereby raising the pretest probability)
the accuracy of LiPA could be maintained even in low
prevalence regions.
Because patients with MDR-TB are more likely to be put
on an effective drug therapy regimen if the drug resistance
is quickly detected, and thus are less likely to transmit
MDR-TB to the community, the benefits of early detection
of drug resistance can be substantial. A positive test in a
high prevalence setting can lead to a highly meaningful
shift from pre-test to post-test probability and thus may
facilitate better outcomes.
LiPA has shown a high degree of accuracy when used on
culture isolates, but this requires 2–6 weeks for primary
isolation. Only four studies applied LiPA directly to clini-
cal specimens, resulting in slightly more variation in the
degree of accuracy than those studies using isolates. Addi-
tional research is needed to establish the accuracy of LiPA
applied to clinical specimens, but the preliminary studies
suggest that LiPA may help diagnose RIF-resistant TB
within 24–48 hours of sample collection.
The cost of the commercial LiPA kit is $45 per sample
tested. When additional costs for import and transport are
taken into account, the actual cost per sample is as high as
$116 [27]. Though this may be prohibitively expensive for
routine use in the regions of the world with the highest
prevalence and incidence of TB and MDR-TB, judicious
use of LiPA for patients with a high likelihood of MDR-TB
(for example, smear-positive patients with treatment fail-
ure or relapse from high incidence areas and/or previously
treated patients) may be possible, particularly when
weighed against the costs of undetected drug resistant TB.
An additional challenge to widespread implementation of
LiPA is the requirement of a lab with technical expertise in
performing PCR.
Strengths and weaknesses of the review
This review has several strengths. We performed a compre-
hensive search for literature by exploring five electronic
databases and by contacting authors, experts, and the
manufacturer of the reviewed index test. Study selection
was conducted independently by two reviewers, as was
data extraction and quality review for a subset of included
studies, and disagreements were resolved with discussion.
We performed meta-analyses in accordance with pub-
lished guidelines [21,22].
This review has some limitations. We excluded studies not
available in English or Spanish language, which could
introduce publication bias. However, a review of the
abstracts of these papers suggests that the overall results
are similar to the results in the included English and Span-
ish language studies. Publication bias may also be intro-
duced by inflation of diagnostic accuracy estimates since
studies that report positive results are more likely to be
accepted for publication. The studies included in this
meta-analysis apply LiPA to a total of 1738 MTB positive
samples, of which 1164 are RIF-resistant. This prevalence
of 67% differs significantly from the prevalence of MDR-
TB seen in routine clinical practice settings, even in high
prevalence regions such as Estonia (14.1%), Henan Prov-
ince in China (10.8%), Latvia (9%), and the Russian
oblasts of Ivanovo (9%) and Tomsk(6.5%) [1]. Because
the specimens analyzed in the studies are not a true repre-
sentation of specimens that a TB laboratory would actu-
ally receive, estimates of sensitivity and specificity may be
inflated. Finally, estimates of sensitivity and specificity
may be inflated in these studies due to exclusion of inde-
terminate results from measures of accuracy if failure
occurred at the PCR stage, which precludes performance
of LiPA on the specimen or isolate.
Implications for research
Additional studies are needed to establish the accuracy of
LiPA used directly on clinical specimens. Study design
should include selection of sputum samples from patients
suspected of having MDR-TB (ie patients with treatment
failure or relapse from high incidence areas and/or previ-
ously treated patients). Indeterminate results, the propor-
tion of RIF-resistant specimens that meet MDR-TB criteria,
patients' sputum smear status, and turnaround time for
diagnosis should be reported.
Studies are also needed to establish clinical usefulness of
rapid diagnosis of RIF-resistant TB in terms of the effect on
clinical outcomes and TB transmission rates. Finally, stud-
ies are needed to establish the cost benefit advantages of
LiPA over conventional DST.BMC Infectious Diseases 2005, 5:62 http://www.biomedcentral.com/1471-2334/5/62
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Conclusion
Line probe assay has been shown to be highly sensitive
and specific in the detection of rifampicin-resistant TB
when used on culture isolates. There is a paucity of data
on application of this test directly to clinical specimens,
although based on a small number of studies, the test
appears to be less promising. The cost of the kit may
render the test impractical for widespread use in those
regions of the world most affected by MDR-TB and most
in need of a method for its rapid diagnosis. However if
further studies indicate that line probe assay consistently
and accurately detects RIF-resistant TB when applied
directly to clinical specimens, it could be a useful test in
select patient populations in which MDR-TB is strongly
suspected.
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